Read down the pageIn accordance with the Exclusive Agreement,...

Read down the page

In accordance with the Exclusive Agreement, sanofi-aventis will receive a ten year extension (“Additional Period”) on its Period of Exclusivity within a designated therapeutic class should sanofi-aventis purchase commercial quantities of the product prior to July 1, 2014. This extension will be reduced on a per therapeutic class basis to five years in the event that sanofi-aventis does not sell a minimum of 20 million units of the Unifill™ syringe for use with
an injectable drug product to be marketed for this therapeutic class in at least one of the first five years of the Additional Period.